DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
| Autor: | Chinyu Su, Walter Reinisch, Nervin Lawendy, Chudy I. Nduaka, Silvio Danese, Gary S. Friedman, Adam S. Cheifetz, Daniel Quirk, Peter D.R. Higgins, Stephen B. Hanauer, Remo Panaccione, Haiying Zhang, Deborah A Woodworth |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Necrosis Tofacitinib Octave (poetry) business.industry Gastroenterology General Medicine medicine.disease Ulcerative colitis 03 medical and health sciences Treatment status 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine 030211 gastroenterology & hepatology medicine.symptom business |
| Zdroj: | Journal of Crohn's and Colitis. 12:S046-S048 |
| ISSN: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjx180.061 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|